From: Controlled ovarian stimulation in cancer patients under 18 years old; a case series
Author; Year | Kutteh et al, 2018 [9] | Peddie et al, 2018 [16] | Lavery et al, 2016 [10] | Oktay et al, 2014 [14] | Reichman et al, 2012 [17] | Kim et al, 2011 [8] | Oktay et al, 2010 [15] | Noyes et al, 2009 [13] | Nagashima et al, 2005 [12] | |||||||||||||||
Patients | 3 | 2 | 1 | 1 | 8 | 7 | 6 | 5 | 4 | 3 | 2 | 1 | 5 | 4 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | |
Diagnosis | Medulloblastoma | myelodysplastic clonef | Sickle cell anemia | ALL | Germ cell tumor | Turner syndrome | Â | Â | Myelodysplastic syndrome | SPH caused by TGVd | Turner syndrome | Ovarian luteinized the coma | AML | 17 | ||||||||||
Age (Menarche age) | 14 (13) | 16 (12) | 14 (13) | 14 (12) | 18 | 18 | 17 | 16 | 16 | 16 | 15 | 14 | 14 (13) | 15 (13) | 14 (11) | 13 (12) | 13 (13) | 13 | 17 | 14 (11) | 19 | 18 | No | |
Ovarian surgery | No | No | No | No | No | No | No | No | No | No | No | No | No | Left oophorectomy | No | No | No | No | No | No | Left oophorectomy | No | No | |
Radiotherapy | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | No | Yes | |
Chemotherapy | No | No | No | No | No | No | No | No | No | No | No | No | Yes | No | No | No | No | No | No | No | No | No | N/Aa | |
AMH (ng/mL) | 12.5g | 6.8g | 13.3g | N/A | 16e | N/A | 24e | 23.8e | N/A | N/A | N/A | N/A | 0.8 | 1.6 | 0.9 | 0.76 | 1.59 | 0.95 | N/A | 0.9 | N/A | N/A | N/A | |
FSH (mIU/mL) | N/A | N/A | N/A | 7.1 | 2.9 | 7.6 | 4.2 | 7.6 | 4.3 | 1.2 | 4.8 | 2 | 7.8 | 5.6 | 5.3 | 5.6 | 5.7 | 5.0 | N/A | 5.3 | N/A | N/A | N/A | |
LH (mIU/mL) | N/A | N/A | N/A | 10.4 | 3.2 | 3.9 | 3.6 | 3.8 | 3.3 | 0.8 | 6.2 | 6.2 | 8.1 | 9.2 | 9.5 | 5.3 | 3.9 | 2.9 | N/A | 9.5 | N/A | N/A | N/A | |
AFC | 31 | 15 | 25 | 17 | 12 | 20 | 20 | 16 | 16 | 18 | 6 | 13 | 5 | 11 | 12 | 6 | 6 | 9 | N/A | 12 | N/A | N/A | N/A | |
COS Protocol | GnRH-antagonist | GnRH-antagonist | GnRH-agonist | GnRH-antagonist | GnRH-antagonist | GnRH-agonist | GnRH-antagonist | GnRH-agonist | N/A | N/A | ||||||||||||||
Duration of stimulation | 10 | 12 | 11 | N/A | 12 | 10 | 11 | 10 | 10 | 11 | 10 | 14 | 12 | 11 | 10 | 10 | 11 | N/A | N/A | N/A | N/A | N/A | N/A | |
Gonadotropins | HMG | HMG | r-FSH | r-FSH (+HMG or r-LH) | HMG | r-FSH (+HMG) | r-FSH (+HMG) | N/A | N/A | N/A | ||||||||||||||
Starting gonadotropin dose (IU) | 150 | 225 | 150 | 225 | 225 | 187.5 | 150 | 150 | 112.5 | 112.5 | 150 | 150 | N/A | N/A | N/A | N/A | N/A | 225 | N/A | 225 (+150)c | 225 (+150)b | N/A | N/A | N/A |
Total gonadotropin dose (IU) | 1800 | 1800 | 1950 | N/A | 3075 | 1875 | 3350 | 1500 | 1462.5 | 1312.5 | 1875 | 2625 | 1775 | 2137.5 | 2075 | 2250 | 2625 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Triggering medication | GnRH-agonist | r-HCG | r-HCG | GnRH-agonist | r-HCG | GnRH-agonist | r-HCG | u-HCG | r-HCG | N/A | GnRH-agonist | N/A | N/A | N/A | ||||||||||
Total oocytes retrieved | 26 | 18 | 25 | 13 | 7 | 31 | 5 | 14 | 29 | 21 | 5 | 7 | 21 | 2 | 11 | 16 | 19 | 20 | 14 | 7 | 11 | 38 | 0 | 0 |
Total mature oocytes (MII) | 17 | 12 | 23 | 12 | 1 | 30 | 3 | 11 | 25 | 16 | 4 | 7 | 10 | 4 | 8 | 7 | 9 | 8 | 8 | 4 | 8 | N/A | 0 | 0 |
OHSS | No | No | No | N/A | No | Yes | No | No | No | No | No | Â | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |